Company intelligence / Profile preview

C4X Discovery

Manchester, England, United Kingdomc4xdiscovery.com ↗

Ownership: Private
Development stage: Phase 1

Overview

C4X Discovery has one candidate in clinical development through Indivior. Their NRF-2 Activator program was licensed to AstraZeneca, and their α4β7 integrin inhibitor program for IBD has shown improved activity at lower doses compared to competitor compounds in pharmacodynamic models after oral dosing.

Therapeutic areas: GastroenterologyPsychiatryImmunologyHematologyOncologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

C4X-6746

Preclinical

Partnerships

SanofiAstraZenecaIndiviorLifeArc

Beyond the preview

Go deeper on C4X Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C4X Discovery.

Explore the full profile